Preeclampsia, characterized by dangerously high blood pressure and organ damage during pregnancy, remains a leading cause of maternal and neonatal morbidity and mortality worldwide. Traditional screening methods in the first trimester primarily rely on maternal risk factors and placental biomarkers, which unfortunately fail to identify over 50% of at-risk pregnancies before the disease’s clinical manifestation. Recognizing this diagnostic gap, the collaborative research initiative spearheaded by the Carlos Simón Foundation and iPremom set out to harness advanced genomics and machine learning for more sensitive, timely detection.

The study enrolled an unprecedented cohort of 9,586 pregnant women across 14 major Spanish hospitals between September 2021 and June 2024. Out of these, a nested case-control subset of 216 participants was meticulously selected for intensive molecular profiling. Researchers collected multiple plasma samples at critical gestational windows—specifically between 9 and 14 weeks, 18 to 28 weeks, and beyond 28 weeks or at diagnosis—to assay circulating cfRNA molecules which serve as dynamic indicators of gene expression changes in maternal and placental tissues.

Employing cutting-edge next-generation sequencing on 548 plasma samples using Illumina technology, the team decoded complex cfRNA profiles. These molecular signatures were then analyzed through sophisticated machine learning algorithms to develop predictive models capable of discerning pregnancies at risk for both early-onset (EOPE) and late-onset preeclampsia (LOPE), well in advance of symptomatic detection.

Remarkably, the first-trimester cfRNA model flagged EOPE with 83% sensitivity and 90% specificity, boasting an average area under the curve (AUC) of 0.88. This implies that on average, the test predicted EOPE approximately 18 weeks—nearly five months—prior to clinical diagnosis. Such temporal advantage presents a compelling opportunity to commence preventative therapies and heightened surveillance protocols, potentially averting severe complications for both mother and child.

Molecular investigation into the predictive transcripts revealed close links to genes involved in maternal endometrial function, particularly those associated with decidualisation resistance. Decidualisation refers to the vital transformation of the uterine lining facilitating embryo implantation and placental development, and its impairment is increasingly implicated in EOPE pathogenesis. Nearly half of the identified cfRNA transcripts corresponded to these uterine remodeling pathways, underscoring a key mechanistic role of uterine dysfunction.

In contrast, cfRNA signatures predictive of LOPE emerged as distinct, with minimal overlap in decidualisation-related transcripts. Instead, late-onset preeclampsia exhibited systemic biological signatures involving immune response and hepatic pathways, emphasizing a more localized and temporally delayed pathophysiology. On average, LOPE was predicted roughly 14.9 weeks before symptom onset, allowing a critical window for early detection despite its complex biological roots.

Dr. Nerea Castillo Marco, the study’s lead author, emphasized the novelty of this approach in prenatal medicine: “Our findings demonstrate for the first time that a routine maternal blood draw during early pregnancy can deliver highly accurate forecasts of preeclampsia, creating an invaluable window for intervention before clinical manifestations.” The precision and non-invasiveness of cfRNA liquid biopsy herald a paradigm shift in maternal-fetal medicine, particularly for a condition historically challenging to diagnose preemptively.

Beyond the predictive capabilities, the transcriptomic landscape mapped in this study provides unprecedented molecular insights into the diverse organ systems impacted during EOPE, including liver, kidney, brain, lungs, and placenta. This multisystem involvement confirms that EOPE encompasses widespread systemic dysregulation rather than isolated placental pathology. Conversely, LOPE’s molecular footprint concentrated on immune and liver-related processes further delineates the two forms as distinct clinical and biological entities.

Project leader Dr. Tamara Garrido highlighted the immediate translational potential: “With ongoing prospective clinical validation underway, we anticipate that cfRNA-based screening will soon integrate seamlessly into routine prenatal care, providing obstetricians worldwide with a robust tool to identify high-risk pregnancies proactively.” Regulatory reviews and clinical deployment efforts are progressing rapidly, with potential availability of this revolutionary screening method expected within the next year.

The implications of this study extend far beyond diagnostics. By elucidating molecular pathways implicated in preeclampsia development, it paves the way for targeted therapeutic research and personalized medicine approaches, aiming to improve maternal and neonatal outcomes on a global scale. This aligns closely with broader public health goals to reduce preventable pregnancy complications and enhance reproductive healthcare equity.

Commenting on these seminal findings, Prof. Dr. Karen Sermon, Chair of ESHRE, stated, “This research not only marks a formidable advance in prenatal disease prevention but also deepens our molecular understanding of preeclampsia—a complex and often enigmatic pregnancy disorder—thus fostering future innovation both in science and clinical practice.”

The study abstract is set to be published imminently in Human Reproduction, one of the world’s foremost journals dedicated to reproductive biology and medicine. This milestone discovery underscores the power of integrating omics technologies with clinical obstetrics, heralding an era where early molecular diagnostics will become central to safeguarding maternal and fetal health worldwide.

Subject of Research: Early detection of preeclampsia using cell-free RNA liquid biopsy in maternal plasma during the first trimester.

Article Title: (Not provided)

News Publication Date: Monday, 30 June 2025

References:
[1] Castillo Marco, N., et al. (2025) Maternal plasma cell-free RNA as a liquid biopsy for first-trimester screening of early and late-onset preeclampsia. Nature Communications (Under review) [preprint] & Human Reproduction (abstract forthcoming)
[2] World Health Organization. (2025). Pre-eclampsia – Fact Sheet.
[3] Muñoz-Blat, R., Pérez-Moraga, R., Castillo Marco, N., et al. (2025). Multi-omics-based mapping of decidualisation resistance in patients with a history of severe preeclampsia. Nature Medicine.

Keywords: Human reproduction, Pregnancy, Preeclampsia, Cell-free RNA, Liquid biopsy, First-trimester screening, Prenatal diagnostics, Maternal plasma, Decidualisation resistance, Obstetrics, Molecular biomarkers, Machine learning

This innovative research leveraged data from a substantial cohort, encompassing over 9,000 pregnancies involved in the collaborative Miracle of Life study. The meticulous analysis led to the identification and validation of unique RNA signatures tied to both mild and severe forms of hypertensive disorders during pregnancy, with a particularly strong focus on preeclampsia. One of the most compelling findings emerged from the use of a simple blood test designed to predict preeclampsia as early as the 17.5 to 22-week gestational window, even in pregnancies devoid of prior high-risk indicators. Such early detection could herald a paradigm shift in the management of at-risk pregnancies.

Dr. Kara Rood, a maternal-fetal medicine specialist and a pivotal investigator in the study, stressed the urgency associated with preeclampsia diagnosis. She articulated the grim reality wherein women often face a race against time once symptoms become evident, necessitating immediate interventions to safeguard both maternal and fetal health. Current guidelines, while informative, lack precision in identifying women who are genuinely at elevated risk for developing severe forms of HDP. In contrast, the Mirvie blood test introduces a new dimension, offering physicians a tool to enhance risk assessments and thereby implement timely preventive measures.

Despite established recommendations from entities like the U.S. Preventive Services Task Force and the American College of Obstetrics and Gynecology, preeclampsia rates have surged alarmingly, nearly doubling over the past decade. At present, the condition now afflicts an alarming one in twelve pregnancies in the U.S. Mirvie’s approach stands out because it employs RNA signatures to provide a far more accurate depiction of risk, allowing practitioners to concentrate their efforts on the one in four pregnancies that truly warrant intervention.

The validation results from the study are particularly promising, indicating that the novel blood test can accurately identify up to 91% of pregnancies likely to develop preterm preeclampsia among women aged 35 and over, all without any existing high-risk conditions. Furthermore, those women who receive a low-risk result from the test enjoy a remarkable 99.7% probability of not experiencing preterm preeclampsia—a statistic that could immeasurably lessen maternal and fetal health complications.

Dr. Thomas McElrath, who serves as the vice president of clinical development at Mirvie, remarked on the significant implications of these findings. He noted that the study not only reveals distinctive molecular signatures that differentiate between various levels of hypertensive disorders but also sets the stage for a proactive model of care in obstetrics. This shift from a largely reactive approach—characterized by interventions only after symptoms arise—towards a strategic preventive model could redefine standards of care in managing at-risk pregnancies.

In addition to the enhanced predictive capabilities the test offers, it also responds to a dire need within the current healthcare landscape, where adherence to preventive interventions such as daily aspirin therapy remains disappointingly low, even among high-risk pregnancies. With the availability of an early, straightforward blood test, healthcare providers can proactively devise personalized care plans well before any complications arise, ultimately improving the odds for full-term pregnancies and assuring healthier outcomes for mothers and babies alike.

Maneesh Jain, CEO and co-founder of Mirvie, expressed enthusiasm about the results stemming from their research investments and collaborations with esteemed experts in maternal-fetal medicine. He emphasized the importance of harnessing molecular subtyping in managing hypertensive disorders of pregnancy, drawing a parallel to how similar advancements in breast cancer research have ushered in better treatment outcomes. This spotlight on molecular signature research offers hope for more tailored interventions and underscores the potential for revolutionizing pregnancy care practices, particularly as instances of complications continue to rise.

The findings from this extensive study contribute to a growing body of literature underscoring the efficacy of RNA platforms in predicting pregnancy-related complications before they develop into severe health crises. Previous research published in journals such as the American Journal of Obstetrics and Gynecology has also demonstrated the utility of Mirvie’s RNA analysis technology in forecasting other pregnancy complications such as preterm birth, thereby solidifying the company’s position at the forefront of maternal health innovation.

Mirvie’s RNA platform marries cutting-edge transcriptomic analysis with advanced machine learning techniques, crafting a detailed portrait of the biological underpinnings of developing pregnancies. The comprehensive analysis performed on nearly 11,000 pregnancies highlighted the capabilities of this innovative platform, which translated vast datasets of cell-free RNA transcripts into actionable insights that can inform clinical practices. As a result of this synergy between big data and genomic research, Mirvie is poised to redefine preventive strategies for a conclusive range of pregnancy complications, including but not limited to gestational diabetes and fetal growth restriction.

The commitment of Mirvie extends beyond technological innovation; the company aims to address some of the most pressing challenges in women’s health surrounding pregnancy complications. With one in five pregnancies experiencing serious complications in the U.S., Mirvie is at the vanguard of ensuring that future pregnancies can be managed with greater safety and fewer health risks. Supported by an impressive roster of investors and backed by a formidable team of seasoned entrepreneurs and scientists, Mirvie seeks to achieve a monumental shift in how pregnancies are viewed, managed, and treated, setting the stage for a more informed and health-conscious approach to maternal care.

In concluding thoughts, the findings from the research reflect a pivotal moment for obstetrics and maternal health, where advancements in molecular science present unique opportunities to transcend traditional care models. As more comprehensive understanding of the biology surrounding pregnancy-related complications emerges, the promise of personalized medicine in obstetrics becomes increasingly tangible, heralding a future where both mothers and infants can enjoy healthier and safer pregnancies.

Subject of Research: Hypertensive Disorders of Pregnancy
Article Title: Molecular Subtyping of Hypertensive Disorders of Pregnancy
News Publication Date: 8-Apr-2025
Web References: Mirvie, Nature Communications
References: U.S. Preventive Services Taskforce, American College of Obstetrics and Gynecology, Journal of the American Medical Association
Image Credits: N/A

Keywords: Pregnancy, Hypertensive Disorders, Preeclampsia, RNA Signatures, Maternal-Fetal Medicine, Preventive Care, Personalized Medicine, Prenatal Care, Health Innovations